Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22714768 | 0.86 | P2RX3 (0.45) | P2RX3P2RX2 | |
| SCHEMBL29481339 | 0.86 | P2RX3 (0.45) | P2RX3P2RX2 | |
| SCHEMBL29676571 | 0.85 | P2RX3 (0.45) | P2RX3P2RX2 | |
| SCHEMBL22714698 | 0.85 | P2RX3 (0.45) | P2RX3P2RX2 | |
| SCHEMBL28931616 | 0.85 | P2RX3 (0.58) | P2RX3P2RX2 | |
| SCHEMBL22714747 | 0.84 | P2RX3 (0.44) | P2RX3P2RX2 | |
| SCHEMBL29676351 | 0.84 | P2RX3 (0.44) | P2RX3P2RX2 | |
| SCHEMBL29481177 | 0.84 | PIK3R1 (0.40) | P2RX3P2RX2 | |
| SCHEMBL28726593 | 0.84 | PIK3R1 (0.40) | P2RX3P2RX2 | |
| SCHEMBL22714750 | 0.81 | P2RX3 (0.45) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | claimed |
| CN-113891745-B | As P2X3Aminoquinazoline derivatives of inhibitors | 奇斯药制品公司 | 2024-05-07 | — | — | CN | claimed |
| EP-3976180-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2022-04-06 | — | — | EP | claimed |
| CN-113891745-A | As P2X3Aminoquinazoline derivatives as inhibitors | 奇斯药制品公司 | 2022-01-04 | — | — | CN | claimed |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-11-11 | — | — | US | disclosed |
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | CHARLES RIVER LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227749-A1 | AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS | P2RX3, P2RX5, P2RX1 | P2RX3 1/4885P2RX2 4/4885 |
| US-12466820-B2 | Amino quinazoline derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX1 | P2RX3 1/4885P2RX2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.